Boston Pharmaceuticals is a clinical-stage biopharmaceutical company. We are developing highly engineered targeted therapies for patients with serious liver diseases. Our lead investigational program, efimosfermin alfa (BOS-580), is a long-acting once-monthly FGF21 analogue being studied in a Phase 2 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). Our second investigational program, BOS-342, is a targeted immunotherapy currently being studied in a Phase 1 clinical trial for the treatment of liver cancer.

Data-Driven Drug Development Engine

Boston Pharmaceuticals has a proven team and a deep network of partners to advance programs through translational and clinical development at an exceptional level. Our team of scientists and clinicians have expertise across multiple disease areas, mechanisms, and molecule types.

We are data-driven and rigorously pursue a thorough understanding of the biology, mechanism, and potential therapeutic differentiation before committing to a program. We align our development strategy with a patient centric perspective to develop drugs and strive to understand the differentiation in our assets and to deliver value to patients, partners, and investors.

Disciplined Approach to Drug Development

Our Expert Team Designs and Leads Our Programs

Complementing the Boston Pharmaceuticals team is a network of best-in-class development partners strategically integrated into our programs. This blended model allows us to flexibly scale across programs, return more value to our partners and ultimately bring the best medicines to patients.